Assessment of CD8(+) T cell differentiation in Trypanosoma cruzi-infected children.

We previously reported that the T cell compartment in chronically Trypanosoma cruzi-infected adult subjects display functional and phenotypic signs of immune senescence. This study aimed to investigate the differentiation and the senescent profile of the overall CD8(+) T cell compartment in T. cruzi-infected children at the early stage of the disease. We found a lower percentage of naive (CD27(+)CD28(+)CD45RA(+)) and early antigen-experienced (CD45RA(-)CD27(+)CD28(+)), and higher percentages of late differentiated antigen-experienced (CD45RA(-)CD27(-)CD28(-)) CD8(+) T cells in T. cruzi-infected children as compared with age-matched uninfected controls. The expression of the interleukin (IL)-7R is also decreased on naive and on antigen-experienced total CD8(+) T cells with various degrees of differentiation. Conversely, the expression of HLA-DR, caspase-3, and CD57 did not vary on the total CD8(+) T cell compartment. These findings suggest that the duration of the infection is relevant in the process of immune senescent that this parasite can induce.

[1]  R. Tarleton,et al.  Changes in Trypanosoma cruzi-specific immune responses following treatment: surrogate markers of treatment efficacy , 2010 .

[2]  R. Tarleton,et al.  Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Tarleton,et al.  Chronic Human Infection with Trypanosoma cruzi Drives CD4+ T Cells to Immune Senescence1 , 2009, The Journal of Immunology.

[4]  S. Kaech,et al.  Diversity in CD8(+) T cell differentiation. , 2009, Current opinion in immunology.

[5]  J. Marin-Neto,et al.  Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas’ disease , 2008, Heart.

[6]  P. Leiva.  Faculty Opinions recommendation of Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. , 2008 .

[7]  Janko Nikolich- Zcaron,et al.  Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. , 2008 .

[8]  A. Teixeira-Carvalho,et al.  Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. , 2008, Microbes and infection.

[9]  J. Nikolich-Žugich.  Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections , 2008, Nature Reviews Immunology.

[10]  R. Tarleton.  Immune system recognition of Trypanosoma cruzi. , 2007, Current opinion in immunology.

[11]  M. Farrar,et al.  IL-7/STAT5 Cytokine Signaling Pathway Is Essential but Insufficient for Maintenance of Naive CD4 T Cell Survival in Peripheral Lymphoid Organs1 , 2007, The Journal of Immunology.

[12]  A. Teixeira-Carvalho,et al.  Benznidazole Treatment during Early‐indeterminate Chagas’ Disease Shifted the Cytokine Expression by Innate and Adaptive Immunity Cells toward a Type 1‐modulated Immune Profile , 2006, Scandinavian journal of immunology.

[13]  R. Tarleton,et al.  Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. , 2006, International immunology.

[14]  R. Tarleton,et al.  Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. , 2004, The Journal of infectious diseases.

[15]  Tao Dong,et al.  Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection , 2004, PLoS biology.

[16]  Andrew J. McMichael,et al.  Characterization of the CD4+ T Cell Response to Epstein-Barr Virus during Primary and Persistent Infection , 2003, The Journal of experimental medicine.

[17]  A. Telenti,et al.  Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection. , 2002, Blood.

[18]  A. McMichael,et al.  CD8(+) T-cell selection, function, and death in the primary immune response in vivo. , 2000, The Journal of clinical investigation.

[19]  R. Corrêa-Oliveira,et al.  Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. , 2000, The Journal of infectious diseases.

[20]  Riarte,et al.  Soluble platelet selectin (sP‐selectin) and soluble vascular cell adhesion molecule‐1 (sVCAM‐1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease , 1999, Clinical and experimental immunology.

[21]  E. Segura,et al.  Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. , 1998, The American journal of tropical medicine and hygiene.

[22]  R. Coffman,et al.  IFN-gamma in human Chagas' disease: protection or pathology? , 1998, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[23]  Simonne Almeida e Silva,et al.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection , 1996, The Lancet.

[24]  R. Rabin,et al.  Altered representation of naive and memory CD8 T cell subsets in HIV-infected children. , 1995, The Journal of clinical investigation.

[25]  M. Miles.  Control of Chagas disease. Report of a WHO Expert Committee. , 1993, World Health Organization technical report series.

[26]  F. Laranja,et al.  Chagas' Disease: A Clinical, Epidemiologic, and Pathologic Study , 1956, Circulation.